Vanda Pharmaceuticals(VNDA)
Focus: Vanda is a public specialty pharmaceutical company focused on rare neurological and psychiatric disorders with a portfolio of small-molecule therapeutics. The company generates nearly half its revenue from HETLIOZ (tasimelteon), a melatonin receptor agonist for sleep-wake disorders.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Vanda Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Vanda Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Vanda Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$193M
Key Products
$96MStable
Peak14.3yr
Flagship product generating 46% of company revenue; melatonin receptor agonist with 15+ year patent protection.
Help build intelligence for Vanda Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.